SynAct Pharma's Chief Business Officer Mads Bjerregaard & Chief Scientific Officer Thomas Jonassen join us for an interview. Further analysis of the Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development - FDA discussions on trial design planned for Q4 2026.
Link to video: https://youtu.be/JgLuUSwLwyI